

## Curriculum Vitae

**Marc André Schneider** Dr. rer. nat.  
d.o.b. October 09th, 1982, in Hachenburg, Germany

### University Education

2008-2011 Doctorate in Biology, JGU  
2003-2008 Diploma in Biology, Johannes Gutenberg-University Mainz (JGU), Germany

### Scientific Career

Since 2020 Principle Investigator in the disease area Lung Cancer and for the Platform Biobanking in the DZL  
Since 2015 Deputy Head of the Lung Biobank Heidelberg, Thoraxklinik at Heidelberg University Hospital, Heidelberg  
Since 2012 Postdoctoral Fellow, Translational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg  
2011-2012 Postdoctoral Fellow, Department of Medical Microbiology and Hygiene, University Medical Center of the JGU  
2008-2011 PhD student, Department of Medical Microbiology and Hygiene, University Medical Center of the JGU

### Awards and Honors

2019 Regionalpreis Mainz "MYPOP/P42POP"

### Citation Record

Total citations: 2,827; h-index:21 (Research Gate July 08<sup>th</sup>, 2024)

### Top-10 selected Publications

Richtmann S, Marwitz S, Muley T, Koistinen H, Christopoulos P, Thomas M, Kazdal D, Allgäuer M, Winter H, Goldmann T, Meister M, Klingmüller U, **Schneider MA**. The pregnancy-associated protein glycodelin as a potential sex-specific target for resistance to immunotherapy in non-small cell lung cancer. *Transl Res.* 2024 Mar 13:S1931-5244(24)00036-7. doi: 10.1016/j.trsl.2024.02.007. Epub ahead of print. PMID: 38490536.2024

Sikosek T, Horos R, Trudzinski F, Jehn J, Frank M, Rajakumar T, Klotz LV, Mercaldo N, Kahraman M, Heuvelman M, Taha Y, Gerwing J, Skottke J, Daniel-Moreno A, Sanchez-Delgado M, Bender S, Rudolf C, Hinkfoth F, Tikk K, Schenz J, Weigand MA, Feindt P, Schumann C, Christopoulos P, Winter H, Kreuter M, **Schneider MA**, Muley T, Walterspacher S, Schuler M, Darwiche K, Taube C, Hegedus B, Rabe KF, Rieger-Christ K, Jacobsen FL, Aigner C, Reck M, Bankier AA, Sharma A, Steinkraus BR. Early Detection of Lung Cancer using small RNAs. *J Thorac Oncol.* 2023 Jul 10:S1556-0864(23)00670-6. doi: 10.1016/j.jtho.2023.07.005. Epub ahead of print. PMID: 37437883.

Schwartz U, Llamazares Prada M, Pohl ST, Richter M, Tamas R, Schuler M, Keller C, Mijosek V, Muley T, **Schneider MA**, Quast K, Hey J, Heußel CP, Warth A, Winter H, Serçin Ö, Karmouty-Quintana H, Jyothula SS, Patel MK, Herth F, Koch I, Petrosino G, Titimeau A, Mardin BR, Weichenhan D, Jurkowski TP, Imbusch CD, Brors B, Benes V, Jung B, Wyatt D, Stahl HF, Plass C, Jurkowska RZ. High-resolution transcriptomic and epigenetic profiling identifies novel regulators of COPD. *EMBO J.* 2023 Jun 15;42(12):e111272. doi: 10.15252/embj.2022111272. Epub 2023 May 5. PMID: 37143403; PMCID: PMC10267701

Trefzer TB\*, **Schneider MA\***, Jechow K, Chua RL, Muley T, Winter H, Kriegsmann M, Meister M, Eils R, Conrad C. Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female

Smokers and Never Smokers. *Cancer Res.* 2022 Sep 2;82(17):3116-3129. doi: 10.1158/0008-5472.CAN-21-3836. PMID: 35819252.\*equal contribution

**Schneider MA**, Rozy A, Wrenger S, Christopoulos P, Muley T, Thomas M, Meister M, Welte T, Chorostowska-Wynimko J, Janciauskiene S. Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study. *Front Oncol.* 2022 Jan 31;12:772076. doi: 10.3389/fonc.2022.772076. PMID: 35174082; PMCID: PMC8841510.

**Schneider MA**, Richtmann S, Gründing AR, Wrenger S, Welte T, Meister M, Kriegsmann M, Winter H, Muley T, Janciauskiene S. Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma. *Int J Oncol.* 2022 Apr;60(4):39. doi: 10.3892/ijo.2022.5329. Epub 2022 Feb 25. PMID: 35211754; PMCID: PMC8878627.

Wessels, S.; Muley, T.; Christopoulos, P.; Meister, M.; Heinzmann-Groth, I.; Warth, A.; Herpel, E.; Hummel, S.; Klingmüller, U.; Kuon J., Schneider, M.A. Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. *Transl Lung Cancer Res*2020, doi: 10.21037/tlcr-20-137.

**Schneider MA**, Muley T, Weber R, Wessels S, Thomas M, Herth FJF, Kahn NC, Eberhardt R, Winter H, Heussel G, Warth A, Herold-Mende C, Meister M. Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. *Cancers* 2018: 10(12).

**Schneider MA**, Muley T, Kahn NC, Warth A, Thomas M, Herth JF, et al. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma. *Oncotarget*, 2016 Oct 4. doi: 10.18632/oncotarget.12474.

**Schneider MA**, Granzow M, Warth A, Schnabel PA, Thomas M, Herth FJF, Dienemann H, Muley T, Meister, M. Glycodelin: A new Biomarker with Immunomodulatory Functions in Non-Small Cell Lung Cancer. *Clin Cancer Res* 2015 Aug 1;21(15):3529-40. doi: 10.1158/1078-0432.CCR-14-2464